Community Health Systems Inc
XMUN:CG5

Watchlist Manager
Community Health Systems Inc Logo
Community Health Systems Inc
XMUN:CG5
Watchlist
Price: 2.4 EUR 0.84% Market Closed
Market Cap: €1.1B

Community Health Systems Inc
Investor Relations

Community Health Systems runs a large network of general acute care hospitals and related outpatient facilities in smaller and mid-sized communities across the United States. It treats patients who need emergency care, surgery, maternity services, and other routine hospital services, and it often acts as the main hospital provider in the areas it serves. The company makes money mainly by billing patients, insurers, and government health programs for hospital stays, doctor services tied to its facilities, imaging, lab work, and outpatient procedures. It also earns fees from affiliated physician practices and other care sites connected to its hospitals. What makes its business model distinct is that it sits at the center of local healthcare delivery rather than selling a product. Its value comes from owning or managing hospitals that community residents rely on for essential care, which gives it a steady role in the healthcare system and ties its fortunes to local demand, insurance coverage, and hospital reimbursement rules.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Apr 22, 2026
AI Summary
Q1 2026

EBITDA: Community Health Systems reported first-quarter adjusted EBITDA of $309 million, at the low end of expectations, with margin pressure tied to weaker volumes, payer mix, and the drag from recent divestitures.

Volume softness: Management said patient volumes were broadly soft across markets, especially for commercial and exchange patients, and blamed a mix of macro pressure and tougher managed care behavior.

Guidance unchanged: Full-year 2026 guidance was left unchanged, with adjusted EBITDA still expected to be $1.34 billion to $1.49 billion.

Balance sheet: The company continued deleveraging, ending the quarter at 6.5x leverage, with additional liquidity expected from the pending Arkansas hospital sale.

Growth investments: CHS is leaning harder into ambulatory surgery centers, including its largest acquisition since 2016 and two new de novo centers, while management said these moves are meant to extend its care networks rather than enter new markets.

Second-half view: Management still expects demand to improve later in the year and said the second quarter should face an easier comparison, but volume recovery is not expected until the back half of 2026.

Key Financials
Adjusted EBITDA
$309 million
Adjusted EBITDA margin
10.4%
Same-store net revenue
up 3.1%
Net revenue per adjusted admission
up 3.7%
Same-store adjusted admissions
down 0.5%
Same-store inpatient admissions
down 1.3%
Same-store surgeries
down 2.2%
ED visits
down 2.8%
Cash flows from operations
use of $297 million
Leverage
6.5x
Net debt
$9.3 billion
Gross proceeds from divestitures
more than $1.1 billion
2032 notes redeemed
$223 million
Arkansas hospital sale proceeds
$112 million
ASC investments
approximately $85 million
Georgia state-directed payment revenue
approximately $25 million
Georgia state-directed payment EBITDA
approximately $25 million
Negative EBITDA from recently divested hospitals
approximately $25 million
Average hourly rate increase
2.3%
Contract labor spend
down 11%
Supplies expense as a percentage of net revenue
14.9%
Medical specialist fees
up approximately 11%
Net physicians added
30
Earnings Call Recording
Other Earnings Calls

Management

Mr. Tim L. Hingtgen
CEO & Director
No Bio Available
Mr. Kevin J. Hammons CPA
President & CFO
No Bio Available
Mr. Kevin A. Stockton
Executive Vice President of Operations & Development
No Bio Available
Dr. Lynn T. Simon M.D., MBA
President of Healthcare Innovation & Chief Medical Officer
No Bio Available
Mr. Chad A. Campbell
President of Region 4 Operations
No Bio Available
Mr. Jason K. Johnson
Senior VP & Chief Accounting Officer
No Bio Available
Shelly Schussele
Senior Director of Investor Relations
No Bio Available
Mr. Justin D. Pitt
Executive VP, General Counsel & Assistant Secretary
No Bio Available
Ms. Beth Witte
Senior VP and Chief Compliance & Privacy Officer
No Bio Available
Ms. Tomi J. Galin
Executive Vice President of Corporate Communications, Marketing & Public Affairs
No Bio Available

Contacts

Address
TENNESSEE
Franklin
4000 Meridian Blvd
Contacts
+16154657000.0
www.chs.net
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett